LAS VEGAS NV--(Marketwire - February 15, 2011) - (PINKSHEETS: IPEX) Salus Labs International announced a major breakthrough by signing a Project Cooperation Agreement with Chongqing Pharmaceutical Company, one of a government-owned family of companies earning, in excess of 5 billion dollars worldwide in 2010. By 2015, sales have been projected to exceed $16 billion. The Project Cooperation Agreement, which amount to a Development Contract, provides Salus Labs with a convincing foot hold into the ever-growing China and Asian market.

Salus Labs will launch "White Tiger Energy Blast" as its first product for the Chinese market. The energy formula will be modified to appeal to Chinese taste. Chongqing Pharmaceutical will formulate a specialized quick energy drink "for the Chinese, by the Chinese."

Chongquing will produce, market, and sell White Tiger throughout China, as well as introduce it into other Asian countries. Through the Project Cooperation/Development Agreement, Salus Labs International is approved to introduce additional nutrition and cosmetic products to the most populated country in the world, totaling over 1.3 billion people.

President and CEO Art Wenzlaff remarked, "We are elated at the potential our Agreement offers. Having a Chinese government-backed affiliation of companies as a working partner, offers our startup company a very bright future. We are now able to tap into a much coveted and exclusive market, that quite frankly, is not easily accessible to other companies."

The signing of Salus Labs Project Cooperation/Development Agreement is not merely ceremonial, as Chongqing, working through the Chinese government, has already filed the initial paperwork for the release of White Tiger Energy Blast. These Foundational steps constitute a landmark event in the growth of Salus Labs International.

Notice on Forward-Looking Statements:
The matters set forth in this press release may contain forward-looking statements regarding Salus Labs and its business within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date on which they are made and Salus Labs undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise. Statements are subject to risks and uncertainties that may cause actual results to differ materially.

Contact Information:

For Information Contact:
Investor relations
Gary Patterson